Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
Eli Lilly said it will file for approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, as it succeeds in two more late-stage trials. The drug delivered significant ...
A look at why rent stabilization consistently fails to deliver on its promises. Capital Record provides regular economic commentary from David L. Bahnsen—National Review Institute senior fellow and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results